Markets
Will NICE approve new Alzheimer's treatment funding by November 30, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if NICE (National Institute for Health and Care Excellence) approves funding for the new Alzheimer's treatment by November 30, 2026. The decision must be officially announced by NICE and reported in at least one major healthcare news outlet.
Rules
- Market closes at 11/30/2026.
- Logic weighted resolution applies.
I doubt NICE will approve the funding by that date; the process for new treatments can take longer than expected due to data requirements. Plus, there seems to be significant controversy around the effectiveness of these new treatments.
Rationale:The comment accurately reflects the current situation regarding NICE's evaluation of new Alzheimer's treatments, as confirmed by the search results. It mentions the controversy over treatment effectiveness and the lengthy approval process, both of which are supported by the provided evidence. The argument is logically sound and directly relevant to the market question, with a balanced presentation of logic and minimal emotional bias.
The market seems overly optimistic about NICE approving funding by November. Historical data shows they often take longer to evaluate new treatments, especially with high costs involved.
Rationale:The comment provides a well-reasoned perspective based on historical data regarding NICE's evaluation process, which is factually accurate and relevant to the market question. There are no logical fallacies present, and while it leans slightly on emotional appeal regarding optimism, it maintains a strong logical foundation. The weights reflect the importance of factual accuracy and logical reasoning in this context.
The current odds seem low given the recent positive trial results. Base rates for approval after such promising data suggest this might change.
Rationale:The comment accurately references recent positive trial results and discusses the implications for approval odds, which is relevant to the market question. There are no significant logical fallacies present, and while the emotional appeal is somewhat present, it does not dominate the argument. The weights reflect the importance of factual accuracy and relevance in this context.
It seems like the odds for NICE approving the new Alzheimer's treatment funding are a bit optimistic. While there's definitely a growing push for better dementia care, the regulatory landscape in the UK tends to be cautious, especially for high-cost treatments. The real question is whether the data will support effectiveness and cost-effectiveness; without that, I don't see how they can greenlight it by November 2026. This market might be underestimating the scrutiny these decisions usually face.
I think the approval for new Alzheimer's treatment funding is uncertain; there's still a lot of debate about the effectiveness and cost, so I'm not convinced this will go through by November.
Rationale:The comment accurately reflects the uncertainty surrounding the approval of new Alzheimer's treatment funding, which is supported by ongoing debates about effectiveness and cost. It is logically sound and directly relevant to the market question, with a balanced approach between reasoning and emotional appeal. The weights emphasize the importance of relevance and logical soundness in this context.
the current price feels too high, considering the past NICE decisions. they’ve been conservative lately. what’s changed?
Rationale:The comment accurately reflects NICE's recent conservative decisions, which is a relevant point in assessing the current market price. However, it lacks specific evidence or data to support the claim about the current price being too high, leading to a slightly lower score in Fact Check. The comment is logically sound and free from fallacies, but it could benefit from more detailed reasoning or data to strengthen its argument.
Seems like the odds are way too optimistic here. NICE has been notoriously slow with approvals, and the pushback from public funding concerns isn't helping. I'd say there's a higher chance of delays than people think.
Rationale:The comment accurately reflects NICE's historical slowness in approvals, which is a verifiable fact, hence the score of 80 for Fact Check. It logically argues against the optimism in the market, showing no fallacies, which is why it scores 90 in that category. The relevance is high as it directly addresses the market question, but it does contain some emotional appeal regarding public funding concerns, leading to a slightly lower score in Logic/Emotion. The weights reflect the importance of relevance and logical soundness in this context.
i don’t get how people think NICE will approve this new funding. there’s been so much pushback on drug prices lately, and they’ve been pretty conservative with approvals. even if the treatment shows promise, they might still find a reason to deny it. it’s like they love saying no. just feels risky, and the odds here don’t reflect that.
Rationale:The comment presents a mostly accurate perspective on NICE's conservative approach to drug approvals and the current climate regarding drug pricing, which supports a high Fact Check score. It logically addresses the market question and expresses a reasonable concern about the risks involved, leading to a strong Relevance score. However, the emotional language slightly detracts from the overall logical balance, hence the lower Logic/Emotion score. The weights reflect the importance of factual accuracy and logical reasoning in this context.
NICE has been slow with approvals lately, and in a similar case last year they took months longer than expected. The current odds seem way too optimistic at around 60%. I’d put it closer to 40% rn, especially with the political pushback on healthcare spending. Anyone else feeling this way?
Rationale:The comment provides a mostly accurate assessment of NICE's recent approval pace, which aligns with known trends, though specific data on last year's case is not verified. It logically critiques the current odds and introduces relevant political context, maintaining a sound argument without fallacies. The weights reflect a balanced focus on factual accuracy and relevance, with some emotional appeal in expressing personal sentiment about the odds.
there's no way NICE approves this in time, the data has been shaky and they've rejected stuff like this before. I'm kind of surprised the market thinks it will pass.
Rationale:The comment presents a mostly accurate perspective on NICE's historical decisions and the current state of data, which is somewhat shaky, thus scoring well on fact check. It is logically sound with no major fallacies, directly addressing the market question. However, it leans slightly on emotional appeal regarding surprise at market sentiment, which is why the logic/emotion score is lower. The weights reflect the importance of factual accuracy and logical reasoning in this context.